This HTML5 document contains 41 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/drugbank/drug/DB04867/identifier/drugbank/
n8http://linked.opendata.cz/resource/drugbank/drug/DB04867/identifier/chemspider/
n6http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n11http://linked.opendata.cz/resource/drugbank/drug/DB04867/identifier/pubchem-compound/
xsdhhttp://www.w3.org/2001/XMLSchema#
n9http://linked.opendata.cz/resource/drugbank/drug/DB04867/identifier/pubchem-substance/

Statements

Subject Item
n2:DB04867
rdf:type
n3:Drug
n3:description
Lintitript is a new, highly specific and potent CCK-A receptor antagonist.
n3:generalReferences
# Kreiss C, Schwizer W, Borovicka J, Jansen JB, Bouloux C, Pignol R, Bischof Delaloye A, Fried M: Effect of lintitript, a new CCK-A receptor antagonist, on gastric emptying of a solid-liquid meal in humans. Regul Pept. 1998 Jun 30;74(2-3):143-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9712175
n3:group
investigational
n3:indication
For the treatment of pancreatic cancer and appetite disorders.
owl:sameAs
n6:DB04867
dcterms:title
Lintitript
adms:identifier
n8:108883 n9:10239927 n10:DB04867 n11:122077
n3:mechanismOfAction
Cholecystokinin (CCK) modulates feeding and dopamine-induced behavior in the central and peripheral nervous system. Lintitript antagonizes the effect of cholecystokinin by binding to the cholecystokinin type A (CCK-A) receptor. This action presumably alters feeding habits, however the exact mechanism of action is not known.
n3:IUPAC-Name
n4:271B5B3E-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5B44-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5B43-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5B40-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5B41-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5B42-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5B3C-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5B3D-363D-11E5-9242-09173F13E4C5 n4:271B5B3A-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5B3B-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B5B4A-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5B4B-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5B45-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5B46-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5B48-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5B47-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5B49-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
136381-85-6
n3:category
n3:Bioavailability
n4:271B5B50-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5B52-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5B53-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5B4F-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5B4E-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5B51-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5B3F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5B4C-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5B4D-363D-11E5-9242-09173F13E4C5